D N (Israel) Performance

DNA -- Israel Stock  

ILS 25.70  0.10  0.39%

Macroaxis gives D N performance score of 0 on a scale of 0 to 100. The corporation shows Beta (market volatility) of -1.2258 which denotes to the fact that as returns on market increase, returns on owning D N are expected to decrease by larger amounts. On the other hand, during market turmoil, D N is expected to significantly outperform it.. Even though it is essential to pay attention to D N A historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis approach into predicting future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. D N A Biomedical Solutions Ltd exposes twenty-one different technical indicators which can help you to evaluate its performance. D N A has expected return of -0.5615%. Please be advised to confirm D N A Maximum Drawdown, and the relationship between Information Ratio and Downside Variance to decide if D N A past performance will be repeated sooner or later.
Horizon     30 Days    Login   to change

D N A Relative Risk vs. Return Landscape

If you would invest  2,660  in D N A Biomedical Solutions Ltd on September 21, 2018 and sell it today you would lose (90.00)  from holding D N A Biomedical Solutions Ltd or give up 3.38% of portfolio value over 30 days. D N A Biomedical Solutions Ltd is producing return of less than zero assuming 1.5744% volatility of returns over the 30 days investment horizon. Simply put, 14% of all equities have less volatile historical return distribution than D N A Biomedical Solutions Ltd and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, D N A Biomedical Solutions Ltd is expected to under-perform the market. In addition to that, the company is 1.51 times more volatile than its market benchmark. It trades about -0.36 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.21 per unit of volatility.

D N Market Risk Analysis

Sharpe Ratio = -0.3566
Good Returns
Average Returns
Small Returns
Negative ReturnsDNA

D N Relative Performance Indicators

Estimated Market Risk
  actual daily
 86 %
of total potential
Expected Return
  actual daily
 1 %
of total potential
Risk-Adjusted Return
  actual daily
 1 %
of total potential
Based on monthly moving average D N is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of D N by adding it to a well-diversified portfolio.

D N Performance Rating

D N A Biomedical Solutions Ltd Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Over the last 30 days D N A Biomedical Solutions Ltd has generated negative risk-adjusted returns adding no value to investors with long positions.

D N Alerts

Equity Alerts and Improvement Suggestions

D N A is not yet fully synchronised with the market data
D N A generates negative expected return over the last 30 days
D N A has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 0 in total debt. D N A Biomedical Solutions Ltd has Current Ratio of 0.18 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
This company reported revenue of . Net Loss for the year was (55.48 M).
DNA BIOMED SOLUT has accumulated about 1.52 M in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Additionally see Investing Opportunities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com